Pradžia › Meningioma › Ohio
Meningioma klinikiniai tyrimai Ohio
7 tyrimai dėl Meningioma ieško dalyvių vietose Ohio.
Miestai Ohio
Oficialus tyrimo tekstas (anglų kalba)
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- Strecker Cancer Center-Belpre, Belpre
- Adena Regional Medical Center, Chillicothe
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- ir dar 30
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT02523014A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
- The Ohio State University College of Medicine (OSUCOM), Columbus
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-08 · NCT07428616RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
- Ohio State University Comprehensive Cancer Center, Columbus
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-13 · NCT07150806Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
- Mayfield Brain and Spine, Cincinnati
- Kettering Health, Kettering
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-07-22 · NCT04427384Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Nationwide Children's Hospital, Columbus
Renkami dalyviai1/2 fazė
Amžius nuo 4 iki 39 · Visoms lytims · Atnaujinta 2026-07-20 · NCT05278208Cognitive Status After Removal of Skull Base Meningioma
- Ohio State University Wexner Medical Center, Columbus
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 89 · Visoms lytims · Atnaujinta 2026-05-22 · NCT04635657Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- UH Cleveland Medical Center, Cleveland
- Ohio State University, Columbus
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 90 · Visoms lytims · Atnaujinta 2026-05-14 · NCT05636618Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.